PolyActiva

PolyActiva is a clinical-stage biotechnology and ophthalmology company based in Melbourne, Australia. The company specializes in developing fully biodegradable ocular implants designed for sustained and controlled drug delivery to treat various eye diseases. Utilizing its proprietary PREZIA platform, PolyActiva creates next-generation implants that enable precise, zero-order drug release over extended periods, ranging from one week to over a year.

The company is advancing several products, including the Latanoprost FA SR Ocular Implant, currently in Phase 1 clinical trials for managing intraocular pressure in open-angle glaucoma and ocular hypertension. Another product in early clinical development is the Levofloxacin Ocular Implant, aimed at treating and preventing ocular infections post-surgery. PolyActiva also collaborates with RareSight, Inc. to develop therapies for rare pediatric retinal diseases, leveraging its innovative drug delivery technology.